01.12.2017 | Rapid communication | Ausgabe 1/2017 Open Access

Clinical trials of CAR-T cells in China
- Zeitschrift:
- Journal of Hematology & Oncology > Ausgabe 1/2017
Background
Methods
Results
Distribution of CAR-T trials in China
Beijing
|
30
|
Shanghai
|
22
|
Guangdong
|
20
|
Chongqing
|
15
|
Jiangsu
|
13
|
Others
|
21
|
Chimeric antigen receptors, vectors, and co-stimulatory molecules used in the CAR constructs
Target antigen
|
Diseases
|
CAR
|
Vector
|
NCT no.
|
---|---|---|---|---|
CD19
|
Leukemia, lymphoma
|
4-1BB- CD3ζ
|
RV
|
NCT01864889
|
CD19
|
B cell malignancies
|
CD28, CD137, CD27
|
LV
|
NCT03050190
|
CD19
|
MCL
|
4-1BB-CD3ζ
|
RV
|
NCT02081937
|
CD19
|
Leukemia
|
NA
|
NA
|
NCT03142646
|
CD19
|
B cell lymphomas
|
CD27-CD3ζ
|
LV
|
NCT02247609
|
CD19
|
Leukemia, lymphoma
|
NA
|
NA
|
NCT02349698
|
CD19
|
Elderly relapsed/refractory B cell ALL
|
NA
|
NA
|
NCT02799550
|
CD19
|
Leukemia, lymphoma
|
NA
|
NA
|
NCT02537977
|
CD19
|
B cell leukemia
|
NA
|
NA
|
NCT02644655
|
CD19
|
B cell leukemia and lymphoma
|
NA
|
NA
|
NCT02813837
|
CD19
|
B cell lymphoma
|
NA
|
NA
|
NCT02547948
|
CD19
|
B cell lymphoma
|
CD28-CD3ζ
|
RV
|
NCT02652910
|
CD19
|
Leukemia, lymphoma
|
CD28, CD3ζ
|
LV or RV
|
NCT02456350
|
CD19
|
Recurrent or refractory acute non-T-lymphocyte leukemia
|
NA
|
NA
|
NCT02735291
|
CD19
|
Lymphoma
|
NA
|
NA
|
NCT02728882
|
CD19
|
Leukemia, lymphoma
|
NA
|
NA
|
NCT02546739
|
CD19
|
B cell lymphomas
|
NA
|
NA
|
NCT02842138
|
CD19
|
ALL
|
NA
|
NA
|
NCT02810223
|
CD19
|
ALL
|
CD28-CD137-CD3ζ
|
LV
|
NCT02186860
|
CD19
|
B cell leukemia, B cell lymphoma
|
CD3ζ, CD28, and 4-1BB
|
LV
|
NCT02963038
|
CD19
|
NHL
|
TCRζ, 4-1BB
|
LV
|
NCT03029338
|
CD19
|
B cell ALL
|
TCRζ, 4-1BB
|
LV
|
NCT02975687
|
CD19
|
B cell leukemia and lymphoma
|
NA
|
LV
|
NCT02933775
|
CD19
|
B cell leukemia
|
4-1BB
|
LV
|
NCT02672501
|
CD19
|
Central nervous system B cell acute lymphocytic leukemia
|
NA
|
NA
|
NCT03064269
|
CD19
|
ALL
|
4-1BB
|
LV
|
NCT02965092
|
CD19
|
Acute leukemia
|
NA
|
NA
|
NCT02822326
|
CD19
|
Leukemia, lymphoma
|
CD28 or 4-1BB and a CD3ζ
|
LV or RV
|
NCT03076437
|
CD19
|
Leukemia and lymphoma
|
NA
|
NA
|
NCT02851589
|
CD19
|
Leukemia and lymphoma
|
NA
|
NA
|
NCT02819583
|
CD19
|
DLBCL
|
NA
|
LV
|
NCT02976857
|
CD19
|
Recurrent or refractory B cell malignancy
|
NA
|
NA
|
NCT02782351
|
CD19
|
Leukemia and lymphoma
|
TCRz-CD28, TCRz-CD137
|
NA
|
NCT02685670
|
CD19
|
B cell lymphoma
|
4-1BB, CD3ζ
|
NA
|
NCT03101709
|
CD19
|
ALL
|
NA
|
NA
|
NCT02924753
|
CD19
|
ALL
|
NA
|
NA
|
NCT03027739
|
CD19
|
B cell leukemia
|
NA
|
LV
|
NCT02968472
|
CD19
|
B cell lymphoma
|
CD28ζ
|
NA
|
NCT02992834
|
CD19
|
AML
|
NA
|
NA
|
NCT03018093
|
CD19
|
Systemic lupus erythematosus
|
4-1BB
|
LV
|
NCT03030976
|
CD19
|
NHL
|
NA
|
LV
|
NCT03154775
|
CD19
|
Lymphoma
|
NA
|
NA
|
NCT03086954
|
CD19
|
ALL, CLL, lymphoma
|
CD28 or 4-1BB and CD3ζ
|
NA
|
NCT03191773
|
CD19
|
B cell lymphoma
|
4-1BB-CD28-CD3
|
NA
|
NCT03146533
|
CD19
|
Leukemia
|
NA
|
NA
|
NCT03173417
|
CD19
|
Relapsed or refractory B cell lymphoma
|
4-1BB
|
LV
|
NCT03208556
|
CD19
|
B cell leukemia and lymphoma
|
NCT03166878
|
||
CD19
|
B cell lymphoma
|
NA
|
NA
|
NCT03118180
|
CD19 or CD20
|
Relapse/refractory B cell malignancies
|
NA
|
LV
|
NCT02846584
|
CD19 and CD20
|
DLBCL
|
NA
|
NA
|
NCT02737085
|
CD19 and CD22
|
Hematopoietic/lymphoid cancer
|
TCRζ, 4-1BB
|
NA
|
NCT02903810
|
CD19/CD20
|
B cell leukemia and lymphoma
|
CD3ζ, 4-1BB-CD3ζ
|
RV
|
NCT03097770
|
CD19/CD22
|
B cell malignancy
|
NA
|
RV
|
NCT03185494
|
CD19/CD22
|
B cell leukemia, B cell lymphoma
|
NA
|
LV
|
NCT03098355
|
CD19/CD20/CD22/CD30
|
B-NHL
|
NA
|
NA
|
NCT03196830
|
CD19/CD20
|
B cell malignancy
|
NA
|
NA
|
NCT03207178
|
CD19 and CD20/CD22/CD38/CD123
|
B cell malignancy
|
NA
|
LV
|
NCT03125577
|
Target Antigen
|
Disease
|
CAR
|
Vector
|
NCT no.
|
---|---|---|---|---|
CD20
|
Lymphoma
|
4-1BB-CD3ζ
|
LV
|
NCT01735604
|
CD20
|
B cell lymphoma
|
CD3ζ and CD28
|
RV
|
NCT02965157
|
CD20
|
B cell malignancies
|
NA
|
NA
|
NCT02710149
|
CD22
|
CD19-refractory or resistant lymphoma
|
TCRζ, 4-1BB
|
RV
|
NCT02721407
|
CD22
|
Recurrent or refractory B cell malignancy
|
NA
|
NA
|
NCT02794961
|
CD22
|
B cell malignancies
|
NA
|
NA
|
NCT02935153
|
CD30
|
Lymphoma
|
NA
|
LV
|
NCT02274584
|
CD30
|
HL, NHL
|
NA
|
NA
|
NCT02259556
|
CD30
|
Lymphocyte malignancies
|
NA
|
NA
|
NCT02958410
|
CD33
|
AML
|
4-1BB-CD3ζ
|
RV
|
NCT01864902
|
CD33
|
AML
|
NA
|
NA
|
NCT02799680
|
CD33
|
Myeloid malignancies
|
NA
|
NA
|
NCT02958397
|
BCMA
|
B cell malignancies
|
NA
|
NA
|
NCT02954445
|
BCMA
|
Multiple myeloma
|
TCRζ, 4-1-BB
|
RV
|
NCT03093168
|
CD123
|
Leukemia
|
NA
|
NA
|
NCT02937103
|
CD123
|
AML recurred after allo-HSCT
|
41BB-CD3ζ
|
NA
|
NCT03114670
|
CD138
|
Multiple myeloma
|
4-1BB-CD3ζ
|
RV
|
NCT01886976
|
CD138/BCMA
|
Multiple myeloma
|
NA
|
NA
|
NCT03196414
|
Lewis-Y
|
Myeloid malignancies
|
NA
|
NA
|
NCT02958384
|
Target antigens
|
Diseases
|
CAR
|
Vector
|
NCT no.
|
---|---|---|---|---|
GPC3
|
Hepatocellular carcinoma
|
NA
|
NA
|
NCT02723942
|
GPC3
|
Hepatocellular carcinoma
|
CD3ζ, CD28, and 4-1BB
|
NA
|
NCT02395250
|
GPC3
|
Lung squamous cell carcinoma
|
NA
|
LV
|
NCT02876978
|
GPC3
|
Hepatocellular carcinoma and liver metastases
|
4-1BB
|
NA
|
NCT02715362
|
GPC3
|
Hepatocellular carcinoma
|
4-1BB
|
NA
|
NCT03130712
|
GPC3
|
Advanced hepatocellular carcinoma
|
4-1BB-CD3ζ
|
RV
|
NCT03084380
|
GPC3
|
Hepatocellular carcinoma, squamous cell lung cancer
|
NA
|
NA
|
NCT03198546
|
GPC3
|
Hepatocellular carcinoma
|
NA
|
LV
|
NCT03146234
|
GPC3, mesothelin, CEA
|
Hepatocellular, pancreatic cancer, colorectal cancer
|
NA
|
LV
|
NCT02959151
|
Mesothelin
|
Malignant mesothelioma, pancreatic Cancer, ovarian tumor, triple-negative breast cancer, endometrial cancer, other mesothelin-positive tumors
|
4-1BB-CD3ζ
|
RV
|
NCT02580747
|
Mesothelin
|
Recurrent or metastatic malignant tumors
|
NA
|
NA
|
NCT02930993
|
Mesothelin
|
Pancreatic cancer and pancreatic ductal a denocarcinoma
|
4-1BB
|
NA
|
NCT02706782
|
Mesothelin
|
Solid tumor, adult advanced cancer
|
NA
|
NA
|
NCT03030001
|
Mesothelin
|
Advanced solid tumor
|
NA
|
NA
|
NCT03182803
|
EpCAM
|
Liver neoplasms
|
NA
|
NA
|
NCT02729493
|
EpCAM
|
Stomach neoplasms
|
NA
|
NA
|
NCT02725125
|
EpCAM
|
Nasopharyngeal carcinoma and breast cancer
|
NA
|
LV
|
NCT02915445
|
EpCAM
|
Colon cancer, esophageal carcinoma, pancreatic cancer, prostate cancer, gastric cancer, hepatic carcinoma
|
CD3ζ, CD28
|
LV
|
NCT03013712
|
GD2
|
Neuroblastoma
|
NA
|
LV
|
NCT02765243
|
GD2
|
Relapsed or refractory neuroblastoma
|
NA
|
NA
|
NCT02919046
|
GD2
|
Solid tumor
|
NA
|
LV
|
NCT02992210
|
HER-2
|
Advanced HER-2-positive solid tumors
|
CD3ζ, 4-1BB-CD3ζ
|
NA
|
NCT01935843
|
HER-2
|
Breast cancer
|
CD28-CD3ζ
|
RV
|
NCT02547961
|
HER-2
|
Breast cancer, ovarian cancer, lung cancer, gastric cancer, glioma, pancreatic cancer
|
NA
|
NA
|
NCT02713984
|
EGFR
|
Advanced EGFR-positive solid tumors
|
4-1BB-CD3ζ
|
LV
|
NCT01869166
|
EGFR
|
Advanced solid tumor
|
NA
|
NA
|
NCT03182816
|
EGFR
|
Colorectal cancer
|
4-1BB-CD28-CD3
|
NA
|
NCT03152435
|
EGFRvIII
|
Recurrent glioblastoma multiform
|
NA
|
LV
|
NCT02844062
|
EGFRvIII
|
Glioblastoma multiform
|
NA
|
NA
|
NCT03170141
|
MUC1
|
Malignant glioma of brain, colorectal carcinoma, gastric carcinoma
|
NA
|
NA
|
NCT02617134
|
MUC1
|
Advanced refractory solid tumor (hepatocellular carcinoma, NSCLC, pancreatic carcinoma, triple-negative invasive breast carcinoma)
|
CD28-4-1BB- CD3ζ
|
LV
|
NCT02587689
|
MUC1
|
Advanced solid tumor
|
NA
|
NA
|
NCT03179007
|
CEA
|
Lung cancer, colorectal cancer, gastric cancer, breast cancer, pancreatic cancer
|
NA
|
NA
|
NCT02349724
|
EphA2
|
EphA2-positive malignant glioma
|
NA
|
NA
|
NCT02575261
|
LMP1
|
Nasopharyngeal neoplasms
|
NA
|
NA
|
NCT02980315
|
MG7
|
Liver metastases
|
4-1BB
|
NA
|
NCT02862704
|
CD133
|
Liver cancer, pancreatic cancer, brain tumor, breast cancer, ovarian tumor, colorectal cancer, ALL, AML
|
CD3ζ, 4-1BB-CD3ζ
|
RV
|
NCT02541370
|
HerinCAR-PD1
|
Advanced malignancies
|
NA
|
NA
|
NCT02873390
|
HerinCAR-PD1
|
Advanced solid tumor (lung, liver, and stomach)
|
NA
|
NA
|
NCT02862028
|
PD-L1 CSR
|
Glioblastoma multiform
|
NA
|
NA
|
NCT02937844
|
NY-ESO-1
|
Advanced NSCLC
|
NA
|
LV
|
NCT03029273
|
Zeushield
|
NSCLC
|
NA
|
NA
|
NCT03060343
|
PSCA/MUC1/PD-L1/CD80/86
|
Advanced lung or other cancers
|
NA
|
NA
|
NCT03198052
|
PSMA, FRa
|
Bladder cancer, urothelial carcinoma bladder
|
NA
|
NA
|
NCT03185468
|
Claudin18.2
|
Advanced gastric adenocarcinoma, pancreatic adenocarcinoma
|
NA
|
LV
|
NCT03159819
|
Target antigen
|
Disease
|
Vector
|
NCT no.
|
---|---|---|---|
CD19
|
B cell malignancies
|
LV
|
NCT03050190
|
CD19
|
B cell lymphomas
|
LV
|
NCT02247609
|
CD19
|
B cell leukemia
|
LV
|
NCT02968472
|
CD19/CD22
|
B cell leukemia, B cell lymphoma
|
LV
|
NCT03098355
|
CD19 and CD20/CD22/CD38/CD123
|
B cell malignancy
|
LV
|
NCT03125577
|
CD30
|
Lymphoma
|
LV
|
NCT02274584
|
PSMA, FRa
|
Bladder cancer, urothelial carcinoma bladder
|
NA
|
NCT03185468
|
EGFRvIII
|
Glioblastoma multiform
|
NA
|
NCT03170141
|
GD2
|
Neuroblastoma
|
LV
|
NCT02765243
|
GD2
|
Solid tumor
|
LV
|
NCT02992210
|